Results 151 to 160 of about 2,768 (167)
Some of the next articles are maybe not open access.
Clinical studies with misonidazole.
The British journal of cancer. Supplement, 1978The preliminary details of a randomized clinical trial of misonidazole for the radiotherapy of Grades 3 and 4 cerebral astrocytoma are described. Plasma concentrations of misonidazole and its O-demethylated metabolite, determined by high-pressure liquid chromatography analysis, are reported for 8 patients with astrocytoma, 1 with carcinoma of the ...
C R, Wiltshire +3 more
openaire +1 more source
Plasma concentrations of misonidazole.
Strahlentherapie, 1981The plasma concentrations of misonidazole doses between 0.6 and 2.0 g/m2 were analyzed in respect to the variation within the same patient and between different patients. Peak plasma levels were observed after 2 hours. The mean plasma levels of misonidazole only at 3 hours were 23.8, 47.0 and 76.5 microgram/ml after misonidazole doses of 0.6, 1.2 and 2.
G, Notter, U, Rylander, I, Turesson
openaire +1 more source
Clinical experience with misonidazole.
The British journal of cancer. Supplement, 1978A total of 62 patients with advanced tumours have now been treated by a fractionated course of radiotherapy, with misonidazole. The prime purpose of the administration of the drug to these patients was to determine safe dosage and suitable regimes for use in clinical radiotherapy.
S, Dische, M I, Saunders
openaire +1 more source
Reductive metabolism and DNA binding of misonidazole
Toxicology and Applied Pharmacology, 1989Misonidazole (1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol) is an experimental anticancer drug. Reductive metabolism is thought to be important for the cytotoxicity of misonidazole. In this study, the DNA binding of misonidazole was examined after chemical and enzymatic reduction.
openaire +2 more sources
Misonidazole levels following misonidazole and hyperbaric oxygen exposure
International Journal of Radiation Oncology*Biology*Physics, 1987G. Blekkenhorst, R. Sealy, S. Cridland
openaire +1 more source
Phenytoin-misonidazole: possible metabolic interaction.
Cancer treatment reports, 1980Following iv administration of misonidazole, evidence of decreased plasma half-life (3.8 hours versus 9.1 hours +/- 0.8 [SD] in eight other patients studied) and increased metabolism was observed in a patient receiving continuous phenytoin therapy.
D, Gangji, J G, Schwade, J M, Strong
openaire +1 more source